Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: comparison with cisapride, itopride, and mosapride.
Acotiamide hydrochloride (acotiamide; N-[2-[bis(1-methylethyl) amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl) amino] thiazole-4-carboxamide monohydrochloride trihydrate, Z-338) has been reported to improve meal-related symptoms of functional dyspepsia in clinical studies. Here, we examined the gastroprokinetic effects of acotiamide and its antiacetylcholinesterase activity as a possible mechanism of action in conscious dogs. Acotiamide increased postprandial gastric motor activity in conscious dogs with chronically implanted force transducers and, like itopride, mosapride, and cisapride, exhibited gastroprokinetic activity in these dogs. Furthermore, acotiamide improved clonidine-induced hypomotility and delayed gastric emptying. Acotiamide-enhanced postprandial gastroduodenal motility was suppressed completely by pretreatment with atropine, a muscarinic receptor antagonist. In in vitro studies, acotiamide enhanced acetylcholine- but not carbachol-induced contractile responses of guinea pig gastric antrum strips. Moreover, like itopride and neostigmine, acotiamide inhibited recombinant human and canine stomach-derived acetylcholinesterase (AChE) activity in vitro. The mode of the AChE inhibitory action of acotiamide was selective and reversible. Unlike itopride or mosapride, acotiamide showed no affinity for dopamine D(2) or serotonin 5-HT(4) receptors. With regard to cardiovascular side effects, unlike cisapride, acotiamide did not affect myocardial monophasic action potential duration, QT interval, or corrected QT interval in anesthetized dogs. These results suggest that acotiamide stimulates gastric motility in vivo by inhibiting AChE activity without affecting QT interval. Acotiamide thus represents a beneficial new drug for the treatment of functional dyspepsia involving gastric motility dysfunction, with differences from other prokinetic agents.
Central Research Laboratories, Zeria Pharmaceutical Co., Ltd., Saitama, Japan. yuugo-matsunaga@zeria.co.jp
Yugo
Y
Matsunaga
Takao
T
Tanaka
Koji
K
Yoshinaga
Shigeru
S
Ueki
Yuko
Y
Hori
Runa
R
Eta
Yoshihiro
Y
Kawabata
Kazuyoshi
K
Yoshii
Kenji
K
Yoshida
Toshihiro
T
Matsumura
Shigeru
S
Furuta
Mineo
M
Takei
Jan
J
Tack
Zen
Z
Itoh
D000818:Animals; D001549:Benzamides / Q000737:chemistry / Q000494:pharmacology*; D001593:Benzyl Compounds / Q000737:chemistry / Q000494:pharmacology*; D016466:CHO Cells; D002800:Cholinesterase Inhibitors / Q000494:pharmacology*; D020117:Cisapride / Q000737:chemistry / Q000494:pharmacology*; D006224:Cricetinae; D003412:Cricetulus; D004285:Dogs; D005769:Gastrointestinal Motility / Q000187:drug effects* / Q000502:physiology; D006168:Guinea Pigs; D006329:Heart Conduction System / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008297:Male; D009025:Morpholines / Q000737:chemistry / Q000494:pharmacology*; D013844:Thiazoles / Q000494:pharmacology*
D001549:Benzamides; D001593:Benzyl Compounds; D002800:Cholinesterase Inhibitors; D009025:Morpholines; D013844:Thiazoles; C102254:itopride; C410959:Z 338; C062720:mosapride; D020117:Cisapride